AI chip stocks and pharma names are the focus of options traders Monday as Wall Street rebounds from last week's tech selloff.
NVDA leads the flow. The stock carries an ORTEX total score of 82.4 and momentum at 58.3. Options expiries stretch all the way to September 2026. Traders are active across near-term weekly expirations. The density of expiry dates — 25 active strikes through August — signals unusually heavy positioning in the name.
INTC is drawing attention too. Intel appeared prominently in FT headlines as a "big gainer" in the AI-linked chip revival. ORTEX data shows options expiries clustered into late July and August. That forward positioning suggests traders expect continued volatility around Intel's restructuring story.
Memory chipmaker MU shows one of the longest expiry tails in the sector. New expirations run to September 10. That extended positioning points to traders hedging or speculating well past the next earnings window.
On the pharma side, GILD and MRK both saw a headline double-punch today. A Phase 3 HIV trial met its endpoints. A separate lung cancer trial was discontinued. This binary-outcome news pattern typically triggers sharp options repricing. GILD's expiry structure runs through August with active near-term contracts.
NBIS — Nebius Group — is a name to watch. The UK AI cloud expansion story broke today with the highest possible impact score. With META, MSFT, and NVDA all connected to the Nebius narrative, options flow in those names may reflect read-through bets.
Broader geopolitical risk is also in the picture. Iran missile strikes briefly threatened a fragile ceasefire. That tends to lift hedging demand in SPY puts and energy names.
This is not financial advice.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
